

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

**Regd. Office:** CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,  
Thaltej, Ahmedabad 380 059. Gujarat, India.

**Tele.:** +079 - 40233000

**Online at :** [Info@coronaremedies.com](mailto:Info@coronaremedies.com)

**website :** [www.coronaremedies.com](http://www.coronaremedies.com)

**CIN :** L24231GJ2004PLC044656

February 02, 2026

To,  
Listing Operation Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
(Scrip Code: 544644)

To,  
Listing Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G, Bandra Kurla  
Complex, Bandra (East), Mumbai - 400051  
(SYMBOL: CORONA)

Dear Sir / Madam,

**Sub.: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results of the Company for Q3FY26.

The press release is also being made available on the website of the Company at [www.coronaremedies.com](http://www.coronaremedies.com)

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya  
Company Secretary and Compliance Officer

Encl.: A/a

## Press Release: CORONA Remedies Limited Q3 and Nine Months Dec'25 Results

The Consolidated Revenue from Operations for the quarter and nine months for FY26 stood at ₹ 342.42 Cr. and ₹ 1050.09 Cr. respectively. The Revenue of the above periods grew by 15.0% and 16.3% respectively, on Y-o-Y basis.

PAT <sup>[1]</sup> for the quarter and nine months FY26 was ₹ 55.56 Cr. and ₹ 154.08 Cr. respectively.

The PAT <sup>[1]</sup> of the above periods grew by 23.7% and 30.7% respectively, on Y-o-Y basis.

Ahmedabad, February 02, 2026: CORONA Remedies Limited, today announced the unaudited results for the third quarter and nine months ended December 31, 2025, as approved by its Board of Directors.

### Q3 FY26 Financial Highlights:

Particulars (₹ in Cr.)	Q3 FY26	Nine Months FY26
Revenue from Operations	342.42	1,050.09
EBITDA	83.16	231.42
EBITDA Margin	24.3%	22.0%
Profit After Tax <sup>[1]</sup>	55.56	154.08
Profit After Tax Margin <sup>[1]</sup>	16.2%	14.7%

### Nine Months FY26 Key Financial Metrics:

Particulars	Nine Months FY26
RoE <sup>[1] [2]</sup>	31.1%
RoCE <sup>[1] [2]</sup>	48.0%
OCF to EBITDA	86.3%
Net Working Capital Days	18 Days

<sup>[1]</sup> Excludes onetime statutory impact of New Labour Code ₹ 19.10 Cr. (Post Tax ₹14.29 Cr.)

<sup>[2]</sup> Annualised

**Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:**

*"We are delighted to report a strong financial performance in Q3 and 9MFY26. Revenues for Q3 and 9MFY26 grew by 15.0% and 16.3% respectively on a Y-o-Y basis, outperforming the IPM growth. Adjusted Profit after tax for Q3 and 9MFY26 grew by 23.7% and 30.7% respectively on a Y-o-Y basis while maintaining healthy return ratios. We have been consistently delivering on our guided*

*We have transformed our aspiration of growing Revenues by 15% and PAT by 20% into successful achievement. Our revenues & PAT has grown as per our aspiration in the last 3 quarters and are optimistic of maintaining similar trajectory going forward.*

*Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists' prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.*

*I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business."*

**Earnings Call:**

CORONA Remedies Limited will conduct earnings call at 04:00 PM (IST) on February 03, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date & Time	Tuesday, February 03, 2026, 4:00pm IST (HK/Singapore – 6:30 pm, UK – 10:30 am, USA – 5:30 am ET)
Universal Dial In	+91-22-6280 1259 / +91-22-7115 8160
International Dial In	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Diamond Pass Link	<a href="https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1267675&amp;linkSecurityString=a117abdc0">https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1267675&amp;linkSecurityString=a117abdc0</a>

**About CORONA Remedies Limited:**

CORONA Remedies Limited (CORONA), founded in 2004, is an India focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/ EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 100+ team members including scientists working on new formulation development.

To know more about us, visit [www.coronaremedies.com](http://www.coronaremedies.com)

For further information, please contact: Mr. Sagar Shroff, Strategic Growth Advisors Private Limited (SGA), Mobile: 98205 19303 and Email Id: [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net)

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

\*\*\*\*\*